Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07255248 · ClinicalTrials.gov registry record · Phase 4
Hoffa's Fat Pad Impingement (HFPI)
A Phase 4 study of Hoffa's Fat Pad Impingement, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT07255248: Recruiting Phase 4 study of Hoffa's Fat Pad Impingement, sponsored by Boston Children's Hospital.
NCT07255248 is a Phase 4 study of Hoffa's Fat Pad Impingement that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 62 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07255248, a Phase 4 study of Hoffa's Fat Pad Impingement, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the study is to investigate treatment outcomes for refractory anterior knee pain due to Hoffa's Fat Pad Impingement (HFPI) in young female athletes. Specifically, the study team will study pediatric female athletes with HFPI, and treatment outcomes of US-guided Hoffa's Fat Pad (HFP) corticosteroid injection compared to standard care (physical therapy, bracing, no injection) and saline injection. There will be two arms in this study, 1, a corticosteroid injection and physical therapy and 2, physical therapy and a saline injection. The intent of this study is to measure treatment outcomes, and the research team is not looking at the safety and effectiveness of the lidocaine-methylprednisolone mixture.
Primary Outcome
The IKDC is a patient-reported outcome measure on a 0-100 scale assessing knee function, symptoms, and sports activities, with higher scores indicating better function, and a lower score indicating low function.
Conditions Studied
Interventions
- DRUG methylprednisolone acetate and lidocaine
- DRUG Saline injection (Octreotide LAR placebo)
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Norwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-01-02 |
| Phase | Phase 4 |
What NCT07255248 shows while recruiting
NCT07255248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Hoffa's Fat Pad Impingement appearing as the primary indexed condition, and to 2 interventions - of which methylprednisolone acetate and lidocaine is the first listed.
NCT07255248 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07255248 about?
NCT07255248 is a clinical study titled "Hoffa's Fat Pad Impingement (HFPI)". The aim of the study is to investigate treatment outcomes for refractory anterior knee pain due to Hoffa's Fat Pad Impingement (HFPI) in young female athletes. Specifically, the study team will study pediatric female athletes with HFPI, and treatment outcomes of US-guided Hoffa's Fat Pad (HFP) corti...
What is the current status of trial NCT07255248?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2026-03-01. Estimated completion is 2028-01-02.
What conditions does trial NCT07255248 study?
This clinical trial studies the following conditions: Hoffa's Fat Pad Impingement.
What interventions are being tested in trial NCT07255248?
The interventions under investigation include: methylprednisolone acetate and lidocaine (DRUG), Saline injection (Octreotide LAR placebo) (DRUG).
Who is sponsoring clinical trial NCT07255248?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07255248 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07255248's enrollment target sits among peer trials
62 1110th of 2000 higher than 883 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI